Mycophenolate Mofetil

證據等級: L5

預測適應症: 10 個

Mycophenolate Mofetil: From Transplant Rejection Prophylaxis to HIV Infectious Disease

One-Sentence Summary

Mycophenolate mofetil (MMF) is an immunosuppressant internationally used to prevent organ transplant rejection. The TxGNN model predicts it may have adjunctive benefit in HIV infectious disease, with 10 clinical trials and 20 publications currently associated with this direction, though the strongest direct evidence is limited to a single completed Phase 2 pilot RCT and several small cohort/pharmacokinetic studies.

Quick Overview

Item	Content
Original Indication	Not available in New Zealand regulatory data (drug not marketed); internationally used as an immunosuppressant for prevention of organ transplant rejection
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.86%
Evidence Level	L2
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data from DrugBank is not currently available for this evidence pack. Based on the mechanistic rationale extracted from the underlying evidence, MMF inhibits inosine monophosphate dehydrogenase (IMPDH), depleting the guanosine nucleotide pool inside activated T cells. Since HIV preferentially replicates in activated CD4+ T cells, this depletion may reduce the pool of susceptible target cells and dampen chronic immune hyperactivation — a recognized driver of HIV disease progression — giving MMF a plausible, if indirect, antiretroviral-adjunct rationale.

The connection between the drug's established use (transplant immunosuppression) and the predicted indication (HIV infection) is also clinically grounded: MMF is already the standard post-transplant immunosuppressant used in HIV-positive organ transplant recipients, so its pharmacology and safety behavior in HIV-positive populations is not novel. Multiple cohort and pharmacokinetic studies (e.g., PMID 12352149, 15355127) further support a mechanistic interaction with nucleoside reverse transcriptase inhibitors such as abacavir, where MMF-induced dGTP depletion appears to potentiate antiretroviral activity in vitro and in small clinical cohorts.

However, this remains a research hypothesis rather than an established therapeutic use: the only completed randomized trial (NCT00038272) is a small Phase 2 pilot, one Phase I/II study was withdrawn with zero enrollment (NCT00021489), and a related Phase 3/Phase 4 trial remains in "Unknown" status. The mechanism is biologically plausible but risk-benefit trade-offs between immunosuppression and antiviral effect require careful evaluation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00120419	Phase 4	Unknown	90	MAN2 study: evaluates whether MMF treats chronic immune hyperactivation and preserves CD4+ T-cell count in chronically HIV-1-infected, ART-naive patients; also assesses plasma HIV-1 RNA and disease progression
NCT00247494	Phase 4	Unknown	90	Substudy of MAN2; evaluates effects of MMF on cardiovascular surrogate markers in HIV-1-infected patients
NCT00021489	Phase 1/2	Withdrawn	0	Intended to assess safety, tolerability and antiretroviral activity of MMF added to abacavir in treatment-experienced HIV patients; withdrawn with zero enrollment, no usable data
NCT00038272	Phase 2	Completed	56	Randomized, double-blind, placebo-controlled pilot comparing DAPD vs. DAPD+MMF added to antiretroviral regimens in treatment-experienced HIV patients
NCT00009009	Phase 2	Completed	10	Safety/efficacy of renal transplantation (with MMF as standard post-transplant immunosuppressant) in HIV-infected patients with end-stage renal disease
NCT01453192	Phase 3	Completed	27	Multicenter follow-up of renal transplant outcomes in HIV-1-infected patients under a raltegravir-based regimen; MMF used as standard immunosuppression, not as HIV therapy
NCT00112593	N/A	Completed	5	Allogeneic stem cell transplant with post-transplant cyclosporine/MMF to induce mixed chimerism in HIV-1-infected patients, with or without malignancy
NCT01288131	Phase 3	Terminated	8	RCT of cyclosporine+MMF vs. cyclophosphamide+prednisolone for anti-EPO-associated PRCA; not an HIV trial, included only via TxGNN drug-level linkage
NCT02793544	Phase 2	Completed	80	HLA-mismatched unrelated donor bone marrow transplant with post-transplant cyclophosphamide, sirolimus and MMF for GVHD prophylaxis in hematologic malignancies; not an HIV trial
NCT06869265	Phase 2	Recruiting	56	Thiotepa/busulfan/fludarabine conditioning for haplo-HSCT in elderly high-risk AML patients; not an HIV trial, included only via TxGNN drug-level linkage

Literature Evidence

PMID	Year	Type	Journal	Key Findings
17017956	2006	Review	Current Topics in Medicinal Chemistry	Reviews immunosuppressive drugs, including MMF, as strategies to target chronic immune hyperactivation in HIV disease progression
15213566	2004	RCT (randomized pilot)	Journal of Acquired Immune Deficiency Syndromes	Randomized pilot study of MMF's effect on immune response and viral load during and after HAART interruption in chronic HIV infection
16379601	2005	Cohort	AIDS Research and Human Retroviruses	Found no detrimental immunological effects when combining MMF with HAART in treatment-naive acute/chronic HIV-1 patients
15871638	2005	Cohort	Clinical Pharmacokinetics	PK/PD study of low-dose MMF combined with abacavir, efavirenz and nelfinavir in HIV-infected patients
15355127	2004	Cohort	Clinical Pharmacokinetics	MMF's effect on antiretroviral pharmacokinetics and intracellular nucleoside triphosphate pools
12352149	2002	Cohort	Journal of Acquired Immune Deficiency Syndromes	Adding MMF to abacavir-containing ART depleted intracellular dGTP and decreased plasma HIV-1 RNA in 5 heavily treated patients
15353978	2004	Cohort	AIDS	Compared HAART with vs. without MMF on plasma HIV-1 RNA decay rate and latent reservoir in treatment-naive patients
11391161	2001	Cohort	Journal of Acquired Immune Deficiency Syndromes	Pilot study of MMF as a component of multidrug-resistant HIV-1 therapy in 7 heavily pretreated AIDS patients
17885292	2007	Cohort	AIDS	Evaluated safety, tolerability and antiretroviral activity of DAPD with or without MMF in drug-resistant HIV infection
16515490	2006	Review	Current Pharmaceutical Design	Reviews "virostatic" agents, including MMF, as a strategy to target residual HIV viremia despite HAART

New Zealand Market Information

Mycophenolate mofetil is not currently marketed in New Zealand, and no authorization records are available in the regulatory data reviewed.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the IMPDH-inhibition mechanism offers a biologically plausible rationale for an HIV adjunct role, and one completed Phase 2 pilot RCT plus several cohort/pharmacokinetic studies support feasibility, the evidence remains preliminary (L2) — several related trials were withdrawn, terminated, or left in unknown status. Critically, official safety labeling (warnings/contraindications) is a blocking data gap, and the drug is not currently marketed in New Zealand, so a full safety assessment cannot yet proceed.

To proceed, the following is needed:

Official package insert / prescribing information (warnings, contraindications) — currently a blocking gap preventing initial safety review
Confirmed mechanism-of-action documentation from DrugBank
Updated status/results from the ongoing/unknown-status MAN2 trials (NCT00120419, NCT00247494)
A larger, adequately powered controlled trial specifically testing MMF as HIV adjunct therapy, given the existing Phase 2 evidence is a small pilot
Assessment of New Zealand market access or import pathway, since the drug is not currently marketed there
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.